SCHEMBL15037086

SCHEMBL15037086

CC(C)(C)c1ccc(-c2cnc(-c3ccc(C[C@H](NC(=O)c4ccc(C(C)(C)C)s4)C(=O)N4CCC[C@H]4C(=O)O)cc3)nc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 13/20 0.46
▸ ACE2 Q9BYF1 7/20 0.46
▸ TSHR P16473 1/20 0.45
▸ PRCP P42785 1/20 0.44
▸ MME P08473 1/20 0.41
▸ MMEL1 Q495T6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15037081 1.00 ACE (0.46) ACEACE2TSHRPRCPMME
SCHEMBL17834576 0.95 ACE (0.49) ACEACE2TSHRPRCPMME
SCHEMBL17834573 0.92 ACE (0.42) ACEACE2TSHRPRCPMME
SCHEMBL17459564 0.92 ACE (0.46) ACEACE2TSHRPRCP
SCHEMBL19465507 0.92 ACE (0.46) ACEACE2TSHRPRCP
SCHEMBL17968865 0.92 ACE (0.46) ACEACE2TSHRPRCP
SCHEMBL17968867 0.92 ACE (0.46) ACEACE2TSHRPRCP
SCHEMBL19465510 0.89 L3MBTL1 (0.44) ACEACE2TSHRPRCP
SCHEMBL22384154 0.89 PRCP (0.40) ACEACE2TSHRPRCPMME
SCHEMBL16295171 0.89 L3MBTL1 (0.44) ACEACE2TSHRPRCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 — — WO disclosed
US-9187522-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2015-11-17 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
WO-2014201172-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2014-12-18 — — WO disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
WO-2013090454-A2 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ACE 3137/4885ACE2 3162/4885TSHR 45/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ACE 3137/4885ACE2 3162/4885TSHR 45/4885
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ACE 3129/4885ACE2 3209/4885TSHR 43/4885
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ACE 3129/4885ACE2 3209/4885TSHR 43/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR ACE 2924/4885ACE2 3115/4885TSHR 44/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR ACE 2924/4885ACE2 3115/4885TSHR 44/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R ACE 3137/4885ACE2 3162/4885TSHR 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback